Safety of long-term anticoagulation in patients with brain metastases

Heidi Horstman, Joshua Gruhl, Lynette M Smith, Apar Kishor P Ganti, Nicole A Shonka

Research output: Contribution to journalArticle

Abstract

Anticoagulation is thought to be associated with the risk of intracranial hemorrhage (ICH) in patients with brain metastases; however, the data on this topic are limited. This study was conducted to determine the incidence of ICH associated with anticoagulant use in adult patients with brain metastases. Consecutive patients with brain metastases occurring from 2006 to 2014 were identified from a single-institution database. Long-term anticoagulant therapy was defined as outpatient anticoagulation therapy of CloseSPigtSPi 1 month. Chi-square tests and Fisher’s exact test were used to compare rates of ICH by groups. This cohort included 125 patients with brain metastases. Of these, 64 had primary of non-small cell lung cancer (51.2%). Of these patients, 12/125 (9.6%) patients developed ICH. Neither the primary tumor site nor the number of brain metastases was associated with the development of ICH. ICH incidence was not associated with the use of anticoagulant therapy, with 8/67 (11.94%) patients on outpatient anticoagulation and 4/58 (6.9%) not on anticoagulation experiencing ICH (p = 0.33). The type of treatment did not significantly influence ICH, although those having combined WBRT and SRS were numerically more likely to experience ICH (4/15; 26.67%) of this cohort. In patients on enoxaparin, there was no difference in the incidence of ICH for daily versus twice-daily dosing (p = 1.0). Long-term anticoagulant use is not associated with an increased incidence of ICH in patients with intracranial metastases.

Original languageEnglish (US)
Article number43
JournalMedical Oncology
Volume35
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Intracranial Hemorrhages
Neoplasm Metastasis
Safety
Brain
Anticoagulants
Incidence
Outpatients
Enoxaparin
Chi-Square Distribution
Therapeutics
Non-Small Cell Lung Carcinoma
Databases

Keywords

  • Anticoagulation
  • Brain metastases
  • Intracranial hemorrhage
  • Intratumoral hemorrhage
  • Outpatient anticoagulation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Safety of long-term anticoagulation in patients with brain metastases. / Horstman, Heidi; Gruhl, Joshua; Smith, Lynette M; Ganti, Apar Kishor P; Shonka, Nicole A.

In: Medical Oncology, Vol. 35, No. 4, 43, 01.04.2018.

Research output: Contribution to journalArticle

@article{aa73830d18f544f09fe15678e9039a31,
title = "Safety of long-term anticoagulation in patients with brain metastases",
abstract = "Anticoagulation is thought to be associated with the risk of intracranial hemorrhage (ICH) in patients with brain metastases; however, the data on this topic are limited. This study was conducted to determine the incidence of ICH associated with anticoagulant use in adult patients with brain metastases. Consecutive patients with brain metastases occurring from 2006 to 2014 were identified from a single-institution database. Long-term anticoagulant therapy was defined as outpatient anticoagulation therapy of CloseSPigtSPi 1 month. Chi-square tests and Fisher’s exact test were used to compare rates of ICH by groups. This cohort included 125 patients with brain metastases. Of these, 64 had primary of non-small cell lung cancer (51.2{\%}). Of these patients, 12/125 (9.6{\%}) patients developed ICH. Neither the primary tumor site nor the number of brain metastases was associated with the development of ICH. ICH incidence was not associated with the use of anticoagulant therapy, with 8/67 (11.94{\%}) patients on outpatient anticoagulation and 4/58 (6.9{\%}) not on anticoagulation experiencing ICH (p = 0.33). The type of treatment did not significantly influence ICH, although those having combined WBRT and SRS were numerically more likely to experience ICH (4/15; 26.67{\%}) of this cohort. In patients on enoxaparin, there was no difference in the incidence of ICH for daily versus twice-daily dosing (p = 1.0). Long-term anticoagulant use is not associated with an increased incidence of ICH in patients with intracranial metastases.",
keywords = "Anticoagulation, Brain metastases, Intracranial hemorrhage, Intratumoral hemorrhage, Outpatient anticoagulation",
author = "Heidi Horstman and Joshua Gruhl and Smith, {Lynette M} and Ganti, {Apar Kishor P} and Shonka, {Nicole A}",
year = "2018",
month = "4",
day = "1",
doi = "10.1007/s12032-018-1101-z",
language = "English (US)",
volume = "35",
journal = "Medical Oncology and Tumor Pharmacotherapy",
issn = "1357-0560",
publisher = "Humana Press",
number = "4",

}

TY - JOUR

T1 - Safety of long-term anticoagulation in patients with brain metastases

AU - Horstman, Heidi

AU - Gruhl, Joshua

AU - Smith, Lynette M

AU - Ganti, Apar Kishor P

AU - Shonka, Nicole A

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Anticoagulation is thought to be associated with the risk of intracranial hemorrhage (ICH) in patients with brain metastases; however, the data on this topic are limited. This study was conducted to determine the incidence of ICH associated with anticoagulant use in adult patients with brain metastases. Consecutive patients with brain metastases occurring from 2006 to 2014 were identified from a single-institution database. Long-term anticoagulant therapy was defined as outpatient anticoagulation therapy of CloseSPigtSPi 1 month. Chi-square tests and Fisher’s exact test were used to compare rates of ICH by groups. This cohort included 125 patients with brain metastases. Of these, 64 had primary of non-small cell lung cancer (51.2%). Of these patients, 12/125 (9.6%) patients developed ICH. Neither the primary tumor site nor the number of brain metastases was associated with the development of ICH. ICH incidence was not associated with the use of anticoagulant therapy, with 8/67 (11.94%) patients on outpatient anticoagulation and 4/58 (6.9%) not on anticoagulation experiencing ICH (p = 0.33). The type of treatment did not significantly influence ICH, although those having combined WBRT and SRS were numerically more likely to experience ICH (4/15; 26.67%) of this cohort. In patients on enoxaparin, there was no difference in the incidence of ICH for daily versus twice-daily dosing (p = 1.0). Long-term anticoagulant use is not associated with an increased incidence of ICH in patients with intracranial metastases.

AB - Anticoagulation is thought to be associated with the risk of intracranial hemorrhage (ICH) in patients with brain metastases; however, the data on this topic are limited. This study was conducted to determine the incidence of ICH associated with anticoagulant use in adult patients with brain metastases. Consecutive patients with brain metastases occurring from 2006 to 2014 were identified from a single-institution database. Long-term anticoagulant therapy was defined as outpatient anticoagulation therapy of CloseSPigtSPi 1 month. Chi-square tests and Fisher’s exact test were used to compare rates of ICH by groups. This cohort included 125 patients with brain metastases. Of these, 64 had primary of non-small cell lung cancer (51.2%). Of these patients, 12/125 (9.6%) patients developed ICH. Neither the primary tumor site nor the number of brain metastases was associated with the development of ICH. ICH incidence was not associated with the use of anticoagulant therapy, with 8/67 (11.94%) patients on outpatient anticoagulation and 4/58 (6.9%) not on anticoagulation experiencing ICH (p = 0.33). The type of treatment did not significantly influence ICH, although those having combined WBRT and SRS were numerically more likely to experience ICH (4/15; 26.67%) of this cohort. In patients on enoxaparin, there was no difference in the incidence of ICH for daily versus twice-daily dosing (p = 1.0). Long-term anticoagulant use is not associated with an increased incidence of ICH in patients with intracranial metastases.

KW - Anticoagulation

KW - Brain metastases

KW - Intracranial hemorrhage

KW - Intratumoral hemorrhage

KW - Outpatient anticoagulation

UR - http://www.scopus.com/inward/record.url?scp=85042799220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042799220&partnerID=8YFLogxK

U2 - 10.1007/s12032-018-1101-z

DO - 10.1007/s12032-018-1101-z

M3 - Article

C2 - 29497873

AN - SCOPUS:85042799220

VL - 35

JO - Medical Oncology and Tumor Pharmacotherapy

JF - Medical Oncology and Tumor Pharmacotherapy

SN - 1357-0560

IS - 4

M1 - 43

ER -